{"name":"Chongqing Peg-Bio Biopharm Co., Ltd.","slug":"chongqing-peg-bio-biopharm-co-ltd","ticker":"","exchange":"","domain":"chongqingpegbiobiopharm.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PJ009","genericName":"PJ009","slug":"pj009","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"PJ009","genericName":"PJ009","slug":"pj009","phase":"phase_3","mechanism":"PJ009 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVGpFSVdrQld4UEVGdklJQmVXdEFvVlVoQmY4T2dWalpTMGJJalN2ZjloV0dFM0hrZmdWeTlUUkVrXzdkZngtZ3ZmRWJyV2lSOWtLNE1Tak9VUzFpWG14TjRES3o3SWs4SENRcWgxaFpvR1lkYkhlS2NqNVZhR3pWMjBaMGlROHRTVWprYURHZXdZbHFGVHA1NmJtWnJvYVJoZE5weFI1d0M2SWtXSEZNYVFlWQ?oc=5","date":"2024-12-31","type":"deal","source":"BioWorld News","summary":"Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld News","headline":"Major 2024 licensing deals confirm Asia’s ascent from copier to innovator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNLVphSUYyb19XalJIeTdKb3VJRmFCN1F3ZUVtMGhaeFozR3B2THRsblQyYW1zcjFfSVZWMXRmRGtSVmdRSmxzV3FHNXV1amVFWE5VcVhmUlBzMWhPQUhhUVlCbkxkZEk5MTBMUzg4MEFLV1NrTGpqbEtqbHNuRmZGclZDNVgwQS12YlNoNkUwMnJoandxZmFXOGlWcml0dWlSYWsweVVPSnJKaG1kOFU1MnV2NkQwXzM0b3EzQV9uSTliY1ZsZW1OMkRncjJUS21fSmd3?oc=5","date":"2024-06-05","type":"patent","source":"Reuters","summary":"Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic - Reuters","headline":"Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOelJQQ3ZNUWhhZm5PRm83cHotbENTUjZYRy0tMkpHSDVBNVhESmVNQnMzeUEtZko4QV9yUm9jY0lRTkE5Y1R5aDVVZTZqajBxZ2NhSXFBSXFMY0xMdHRDSUMwdXRNWHJDcTdGc2dFSHQ5OFVjbHRnSG1TXzB4ZExfZmIwUHViUXVvT3RSU2FfMVlpYTBuZUpBMFdrMjdpUlI4MlFmZA?oc=5","date":"2024-04-11","type":"regulatory","source":"BioWorld News","summary":"China advances semaglutide biosimilars, Jiuyuan seeks NMPA nod - BioWorld News","headline":"China advances semaglutide biosimilars, Jiuyuan seeks NMPA nod","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}